Systematic response of staurosporine scaffold‐based inhibitors to drug‐resistant cancer kinase mutations

Abstract

Human protein kinases have been established as promising druggable targets in cancer therapy. However, a large number of acquired drug-resistant kinase mutations are observed after first-and second-line kinase inhibitor treatments, largely limiting the application of small-molecule inhibitors in the targeted cancer therapy.Previously, the pan-kinase inhibitor staurosporine and its derivatives have been reported to selectively inhibit gatekeeper mutants over wild-type kinases, suggesting that the staurosporine scaffold is potentially helpful in developing wild-typesparing inhibitors of drug-resistant kinase mutants. Here, a systematic response profile of 32 staurosporine scaffold-based inhibitors (SSBIs) for 61 ontologyenriched drug-resistant cancer kinase mutations is created using a combination of in silico analysis and in vitro assay, from which it is possible to identify those mutations that have the potential to cause resistance or confer sensitivity to SSBIs. The profile reveals that SSBIs exhibit distinct responses to kinase gatekeeper and nongatekeeper mutations, and SSBIs bearing p7 substituents can considerably influence their response to kinase gatekeeper mutations, particularly for the mutations of the Ile residue, which possesses a Cβ methyl group that tends to cause steric clash with bound SSBIs. Nongatekeeper mutations generally have a moderate and unfavorable effect on SSBI activity, as most of them are outside the kinase active site and do not directly contact inhibitor ligands. In addition, it is found that resistance is commonly caused by mutation-induced hindrance effects, whereas sensitivity is primarily conferred by mutation-established additional interactions. K E Y W O R D Sdrug-resistant kinase mutation, inhibitor selectivity, protein kinase, staurosporine scaffold-based inhibitor, targeted cancer therapy

Discovery of New Anti-Cancer Agents against Patient-Derived Sorafenib-Resistant Papillary Thyroid Cancer

“…Clinical behavior based on the molecular and biological mechanisms of anti-cancer drug-sensitive cancer and drug-resistant cancer is distinct [12,13]. Many researchers have focused on making a difference by analyzing the span of mutations between anti-cancer drug-sensitive cancer and drug-resistant cancer [14][15][16][17][18][19][20]. However, the mechanism of the molecular distinctions to fully determine the anti-cancer drug-resistantmediated poor prognosis in patients with PTC is undetermined.…”

Immune infiltration and drug specificity analysis of different subtypes based on functional status in angioimmunoblastic T-cell lymphoma

“…Few studies have focused on the effects of staurosporine. However, as a broadly selective and effective protein kinase inhibitor, it has been hypothesized to play an essential role in treating tumor drug resistance [ 33 ]. Its exact role needs to be further defined.…”

Anti-Cancer SERCA Inhibitors Targeting Sorafenib-Resistant Human Papillary Thyroid Carcinoma

“…It is well known that clinical behavior based on molecular and biological mechanisms is different between anti-cancer drug-sensitive cancer and resistant cancer [ 11 , 12 , 13 ]. Therefore, several studies have shown that the range of mutations affects anti-cancer drug-sensitive and -resistant cancers [ 14 , 15 , 16 , 17 , 18 , 19 ]. Many previous studies have demonstrated molecular diversities to clarify the poor prognosis of PTC in anti-cancer drug-resistant patients; however, to the best of our knowledge, no study has yet provided a clear description of the underlying mechanism.…”